文献速递胸部肿瘤

ALK耐药突变与劳拉替尼在晚期ALK阳性非小细胞肺癌中的疗效

ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
PubMed 文献 · J Clin Oncol · 2019-03-20

基于劳拉替尼注册II期研究的198例晚期ALK阳性非小细胞肺癌患者,分析血浆和组织ALK突变状态与疗效的关系。在至少一种二代ALK TKI治疗失败的患者中,有ALK突变者客观缓解率更高(血浆62% vs 32%;组织69% vs 27%),组织检测有突变者无进展生存期显著更长(11.0 vs 5.4个月;HR 0.47)。

要点

  • 约四分之一患者通过血浆或组织基因分型检出ALK突变。
  • 克唑替尼耐药患者中,有无ALK突变者劳拉替尼疗效相当。
  • 二代ALK TKI失败后,有ALK突变者劳拉替尼疗效更优,组织检测有突变者无进展生存期显著更长。

核心结论

  • 在至少一种二代ALK TKI治疗失败的患者中,劳拉替尼对有ALK突变者的疗效优于无ALK突变者。
  • 二代TKI失败后行肿瘤基因分型检测ALK突变,可能识别更可能从劳拉替尼获得临床获益的患者。

研究设计与样本

  • 来自劳拉替尼注册II期研究的198例ALK阳性非小细胞肺癌患者,采集基线血浆和组织样本。
  • 血浆DNA用Guardant360分析ALK突变,肿瘤组织DNA用聚焦ALK突变的二代测序分析。
  • 按ALK突变状态评估客观缓解率、缓解持续时间和无进展生存期。

主要发现

  • 约四分之一患者通过血浆或组织基因分型检出ALK突变。
  • 克唑替尼耐药患者中,血浆或组织检测有无ALK突变者劳拉替尼疗效相当。
  • 至少一种二代ALK TKI失败患者中,有ALK突变者客观缓解率更高:血浆62% vs 32%;组织69% vs 27%。
  • 血浆基因分型有与无ALK突变者无进展生存期相似:中位7.3个月 vs 5.5个月;HR 0.81。
  • 组织基因分型有ALK突变者无进展生存期显著更长:中位11.0个月 vs 5.4个月;HR 0.47。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Lorlatinib is a potent, brain-penetrant, third-generation anaplastic lymphoma kinase (ALK)/ROS1 tyrosine kinase inhibitor (TKI) with robust clinical activity in advanced ALK-positive non-small-cell lung cancer, including in patients who have failed prior ALK TKIs. Molecular determinants of response to lorlatinib have not been established, but preclinical data suggest that ALK resistance mutations may represent a biomarker of response in previously treated patients. PATIENTS AND METHODS: Baseline plasma and tumor tissue samples were collected from 198 patients with ALK-positive non-small-cell lung cancer from the registrational phase II study of lorlatinib. We analyzed plasma DNA for ALK mutations using Guardant360. Tumor tissue DNA was analyzed using an ALK mutation-focused next-generation sequencing assay. Objective response rate, duration of response, and progression-free survival were evaluated according to ALK mutation status. RESULTS: Approximately one quarter of patients had ALK mutations detected by plasma or tissue genotyping. In patients with crizotinib-resistant disease, the efficacy of lorlatinib was comparable among patients with and without ALK mutations using plasma or tissue genotyping. In contrast, in patients who had failed 1 or more second-generation ALK TKIs, objective response rate was higher among patients with ALK mutations (62% v 32% [plasma]; 69% v 27% [tissue]). Progression-free survival was similar in patients with and without ALK mutations on the basis of plasma genotyping (median, 7.3 months v 5.5 months; hazard ratio, 0.81) but significantly longer in patients with ALK mutations identified by tissue genotyping (median, 11.0 months v 5.4 months; hazard ratio, 0.47). CONCLUSION: In patients who have failed 1 or more second-generation ALK TKIs, lorlatinib shows greater efficacy in patients with ALK mutations compared with patients without ALK mutations. Tumor genotyping for ALK mutations after failure of a second-generation TKI may identify patients who are more likely to derive clinical benefit from lorlatinib.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Shaw AT, Solomon BJ, Besse B, et al. ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2019. PMID: 30892989. doi:10.1200/JCO.18.02236

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。